Pharmaceutical giant Bristol Myers Squibb is currently offering a 4.7% yield. The dividend hasn't been increased every single ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma, by Bristol ...

This initiative marks among the BMS Foundation’s first grants in India to increase access to screening and build capacity to ...

Cobenfy’s efficacy at treating the symptoms of patients with psychosis may vary between subgroups, according to a post-hoc ...

Bristol-Myers Squibb Company (BMY) recently received an upward revision to a “Buy” rating from Seamus Fernandez at Guggenheim, a move that investors view as a significant endorsement amid a ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Beam Therapeutics Inc. has raked in $255 million in cash from the sale of its spinout, Orbital Therapeutics, to Bristol Myers ...

Emerging evidence hints that daily multivitamins might quietly help certain older adults keep their blood pressure in ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything.

Citius Oncology entered into an exclusive distribution agreement with Er-Kim to expand international access to Lymphir (denileukin diftitox-cxdl) in Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia ...